Sprout Investors Say Valeant Overcharging for Female Libido Pill

  • Valeant failed duties to commercialize pill: Sprout investors
  • Valeant bought female libido pill maker for $1 billion in '15

Investors in Sprout, the female libido pill maker bought by Valeant Pharmaceuticals International Inc. for $1 billion last year, said Valeant has failed to successfully commercialize the treatment by setting the price too high and neglecting to market it, putting the drugmaker at risk of violating the merger agreement.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.